BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ahead of the company reporting Q4 results on Friday, February 14. For Q4, the firm’s revenue estimate is decreased 16%, primarily due to lower sales assumptions to align with revised company guidance, while Q4 EPS decreases by a similar amount. For 2025 and 2026, BofA’s revenue estimates decrease 18% and 15%, respectively, the analyst noted in the preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna’s Underperform Rating: Challenges in Revenue Diversification and Forecasting Amid Pandemic Volatility
- VOO ETF News, 2/11/2025
- Options Volatility and Implied Earnings Moves This Week, February 10 – February 14, 2025
- SPY ETF Update, 2/6/2025
- Sell Rating for Moderna Amid Regulatory Concerns and Stock Volatility